Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
also included is a decision on therapy beyond metformin based on presence of #ASCVD and other comorbidities, GLP-1RAs or SGLT2is are suggested
It might be the dose, the titration speed, a concurrent medication, an underlying condition, or a shift to a different GLP-1 medication entirely (tirzepatide, for instance, shows stronger average weight loss in head-to-head comparisons)
If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation
Lizzo JM, Goyal A, Gupta V
cardiovascular and renal benefits observed in trials have broadened clinician interest
US$ 20.30
US$ 22.83
US$ 24.00
US$ 20.17
